Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

209.46
-2.2750-1.07%
Post-market: 209.500.0400+0.02%19:50 EDT
Volume:2.12M
Turnover:444.42M
Market Cap:44.89B
PE:-23.48
High:212.74
Open:212.06
Low:206.75
Close:211.74
52wk High:220.34
52wk Low:35.62
Shares:214.34M
Float Shares:184.00M
Volume Ratio:1.37
T/O Rate:1.15%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9212
EPS(LYR):-5.9502
ROE:-79.09%
ROA:-30.12%
PB:17.23
PE(LYR):-35.20

Loading ...

Alphabet Reports Share Stake in SpaceX, Fervo Energy and Parabilis Medicines

Reuters
·
Aug 07

Alphabet Inc. Cuts Share Stake in Revolution Medicines Inc by 10.5% to 2.9 Mln Shares - SEC Filing

THOMSON REUTERS
·
Aug 07

Bernstein Remains a Hold on Revolution Medicines (RVMD)

TIPRANKS
·
Aug 06

Revolution Medicines is Maintained at Buy by Guggenheim

Dow Jones
·
Aug 06

Wedbush Adjusts PT on Revolution Medicines to $201 From $192.10, Maintains Outperform Rating

MT Newswires Live
·
Aug 06

Analysts Have Conflicting Sentiments on These Healthcare Companies: Revolution Medicines (RVMD), Royalty Pharma (RPRX) and Urogen Pharma (URGN)

TIPRANKS
·
Aug 06

Revolution Medicines, Inc. : Needham Raises Target Price to $240 from $236

THOMSON REUTERS
·
Aug 06

Revolution Medicines Earns Buy as Strong RAS Portfolio Data, Robust Launch Prep, and $5.4B Capital Base Drive Price Target Increase to $291

TIPRANKS
·
Aug 06

Revolution Medicines Publishes Corporate Deck Outlining Ras(on) Inhibitor Pipeline Targeting RAS-Driven Cancers

Reuters
·
Aug 06

Revolution Medicines Q2 2026 Earnings: Daraxonrasib Advances as Spending Rises

TradingKey
·
Aug 06

Earnings Flash (RVMD) Revolution Medicines Posts Q2 Loss $3.06, vs. FactSet Est of $2.04 Loss

MT Newswires Live
·
Aug 06

Revolution Medicines, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 06

Revolution Medicines reports Q2 EPS ($3.06), consensus ($2.06)

TIPRANKS
·
Aug 06

Revolution Medicines Q2 FY26 Net Loss Widens to $644.4 Million; R&D Expenses Rise to $394.9 Million

Reuters
·
Aug 06

Revolution Medicines Q2 EPS $(3.06) Misses $(1.98) Estimate

Benzinga Earnings
·
Aug 06

Revolution Medicines Reports Second Quarter 2026 Financial Results and Update on Corporate Progress

THOMSON REUTERS
·
Aug 06

Movement Alert|Revolution Medicines, Inc. Rises 5.23% in Regular Trading, FDA NDA Acceptance and Pre-Earnings Optimism Drive Multi-Catalyst Rally

Market Focus
·
Aug 05

Revolution Medicines Inc Expected to Post a Loss of $1.98 a Share - Earnings Preview

Reuters
·
Aug 04

Jefferies Cuts Ipsen to 'underperform' on Somatuline Competition Risk

Reuters
·
Aug 03

FDA Priority Review For Daraxonrasib Might Change The Case For Investing In Revolution Medicines (RVMD)

Simply Wall St.
·
Jul 31